RESUMEN
Recurrent aphthous stomatitis (RAS) is a frequently seen oral ulcerative lesion, manifesting as multiple, recurrent, shallow, irregular ulcers encircled by an erythematous halo. The precise etiopathogenesis is obscure, although the recent understanding suggests an underlying immune-mediated etiology. However, there is no defined management protocol and the principal therapy aims to attain symptomatic respite. 150 clinically diagnosed RAS patients of both sexes in the age range of 15-65 years were randomly allocated and divided into two cohorts, namely Group A (75 RAS patients receiving 5% Amlexanox paste + 100 mg Rebamipide tab.) and Group B (75 RAS patients receiving Dologel CT). Effectiveness of 5% Amlexanox oral paste and Rebamipide tablets in diminution of the ulcer size, erythema and pain was assessed and compared with Dologel CT therapy. The study showed an equal gender distribution. Majority of the patients were in the younger age range (25-35 years) and labial and buccal mucosa were the commonest affected sites. Although, both 5% Amlexanox and Rebamipide tablets and Dologel CT showed statistically significant resolution in the ulcer size, erythema, and associated pain. However, 5% oral Amlexanox paste and Rebamipide tablets are more efficacious in the treatment of RAS and tend to heal the ulcer at a more accelerated pace. Our research concluded that 5% oral Amlexanox paste and Rebamipide tablets tend to heal the ulcer at a more accelerated pace as compared to Dologel CT.